TET2 and acquired polycythemia vera: TET2 mutations often occur early during the development of human myeloid malignancies, including PV, ET, MF, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).